A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-05-05
DOI
10.1093/eurheartj/ehaa419
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
- (2019) Subodh Verma et al. DIABETES CARE
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
- (2016) Aki Okamoto et al. Drugs in research & development
- Association Between Visceral and Subcutaneous Adipose Depots and Incident Cardiovascular Disease Risk FactorsCLINICAL PERSPECTIVE
- (2015) Tobin M. Abraham et al. CIRCULATION
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
- (2015) S. P. Rajeev et al. DIABETES OBESITY & METABOLISM
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- (2015) Roberto M. Lang et al. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
- (2013) Sunder Mudaliar et al. Diabetes Technology & Therapeutics
- Allopurinol Reduces Left Ventricular Mass in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy
- (2013) Benjamin R. Szwejkowski et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease
- (2013) Sushma Rekhraj et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients
- (2008) L. M. Ruilope et al. AMERICAN JOURNAL OF HYPERTENSION
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started